Millendo Therapeutics (MLND) Stock Price, News & Analysis

Company Overview

As of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.

Key Stats

• Today's Range: $0.90 to $0.94
• 50-Day Range: $3.06 to $5.84
• 52-Week Range: $0.92 to $16.95
• Volume: 833,144 shs
• Average Volume: 1.52 million shs
• Market Capitalization: $17.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MLND Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Millendo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Millendo Therapeutics investors own include Elbit Systems (ESLT), UnitedHealth Group (UNH), AbbVie (ABBV), American Water Works (AWK), Bright Health Group (BHG), Black Hills (BKH) and Blackrock Municipal 2030 Target Term Trust (BTT).

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:MLND
• CUSIP: N/A
• CIK: N/A
• Web: www.millendo.com
• Phone: 734 845 9000
• Fax: N/A
• Employees: 12
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-36,410,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -91.03%
• Return on Assets: -72.44%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.39
• Quick Ratio: 6.39

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.78 per share
• Price / Book: 0.52

Miscellaneous

• Outstanding Shares: 19,043,000
• Free Float: N/A
• Market Cap: $17.50 million
• Optionable: Not Optionable
• Beta: 0.48